Core Viewpoint - The First Trust Health Care AlphaDEX ETF (FXH) is a smart beta ETF designed to provide broad exposure to the Health Care sector, with a focus on stock selection based on fundamental characteristics [1][5]. Fund Overview - FXH was launched on May 8, 2007, and has accumulated over $868.7 million in assets, making it one of the larger ETFs in the Health Care category [1][5]. - The fund is managed by First Trust Advisors and aims to match the performance of the StrataQuant Health Care Index, which utilizes the AlphaDEX stock selection methodology [5]. Cost and Expenses - FXH has an annual operating expense ratio of 0.60%, which is comparable to most peer products in the space [6]. - The ETF has a 12-month trailing dividend yield of 0.33% [6]. Sector Exposure and Holdings - FXH is fully allocated to the Health Care sector, with approximately 100% of its portfolio dedicated to this area [7]. - The top holding, Biogen Inc. (BIIB), constitutes about 2.36% of the fund's total assets, with the top 10 holdings accounting for approximately 23.06% of total assets under management [8]. Performance Metrics - Year-to-date, FXH has experienced a loss of about -0.94%, and it is down approximately -4.34% over the last 12 months as of August 13, 2025 [10]. - The ETF has traded between $93.63 and $113.83 in the past 52 weeks, with a beta of 0.73 and a standard deviation of 15.85% over the trailing three-year period, indicating a medium risk profile [10]. Alternatives - While FXH is a viable option for investors looking to outperform the Health Care ETFs segment, there are alternative ETFs such as the Vanguard Health Care ETF (VHT) and the Health Care Select Sector SPDR ETF (XLV) that investors may consider [11][12]. - VHT has $14.81 billion in assets and an expense ratio of 0.09%, while XLV has $31.99 billion in assets with an expense ratio of 0.08% [12].

Core Viewpoint - The First Trust Health Care AlphaDEX ETF (FXH) is a passively managed ETF that provides broad exposure to the Healthcare - Broad segment of the equity market, appealing to both institutional and retail investors due to its low cost and tax efficiency [1][2]. Group 1: ETF Overview - FXH was launched on May 8, 2007, and has accumulated over $857.74 million in assets, making it one of the larger ETFs in its category [3]. - The ETF aims to match the performance of the StrataQuant Health Care Index, utilizing the AlphaDEX stock selection methodology to choose stocks from the Russell 1000 Index [3]. Group 2: Costs and Performance - FXH has annual operating expenses of 0.6% and a 12-month trailing dividend yield of 0.34%, which is competitive within its peer group [4]. - The ETF has experienced a loss of approximately 3.39% year-to-date and about 8.07% over the past year, with a trading range between $93.63 and $113.828 in the last 52 weeks [7]. Group 3: Sector Exposure and Holdings - The ETF is fully allocated to the Healthcare sector, with Biogen Inc. (BIIB) representing about 2.36% of total assets, and the top 10 holdings accounting for approximately 23.06% of total assets under management [5][6]. Group 4: Alternatives and Comparisons - FXH carries a Zacks ETF Rank of 3 (Hold), indicating it is a reasonable option for investors seeking exposure to healthcare ETFs [8]. - Other alternatives include the Vanguard Health Care ETF (VHT) with $15.18 billion in assets and an expense ratio of 0.09%, and the Health Care Select Sector SPDR ETF (XLV) with $33.05 billion in assets and an expense ratio of 0.08% [9].